These results suggest that stimulation of the NF-κB pathway may be involved in the enhanced inflammatory response associated with these diseases
2008
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Key concepts
- inflammatory response
- transcription factor
- cytoplasm
- lymphocytes
- nitric oxide
- dominant negative
- apoptosis
- signal transduction
- IκB kinase
- Cyclosporin A
- radiation therapy
- Nonsteroidal anti-inflammatory drugs
- proteasome
- Alzheimer disease
- steroid receptor coactivator-1
- aspirin
- chemotherapy
- cyclopentenone prostaglandins
- CREB-binding protein
Scholarcy highlights
- NF-κB comprises a family of inducible transcription factors that serve as important regulators of the host immune and inflammatory response
- NF-κB regulation of cellular apoptosis and proliferation In addition to activating the expression of genes involved in the control of the immune and inflammatory response, the NF-κB pathway is a key mediator of genes involved in the control of the cellular proliferation and apoptosis
- Treatment of patients with inflammatory bowel diseases with steroids decreases NF-κB activity in biopsy specimens and reduces clinical symptoms. These results suggest that stimulation of the NF-κB pathway may be involved in the enhanced inflammatory response associated with these diseases
- The ΙκBα super-repressor suppresses constitutive and TNF-α–induced NF-κB activity in human head and neck carcinoma cells in tissue culture and reduces the growth of such tumors in SCID mice. These results suggest that the IκBα super-repressor inhibits the expression of NFκB–dependent genes, which can enhance the growth of squamous cell carcinomas
- Inhibition of the NF-κB pathway by immunosuppressive agents Cyclosporin A and tacrolimus are immunosuppressive agents used in organ transplantation to prevent graft-versus-host disease
- Downregulation of the NF-κB pathway by cyclopentenone prostaglandins NF-κB regulates the expression of a variety of genes involved in the immune and inflammatory responses, including COX-2
- It is possible that specific inhibitors of IKK activity may provide a new class of anti-inflammatory and anticancer agents or of adjunct therapeutics to enhance the efficacy of other cancer therapies
Need more features? Save interactive summary cards to your Scholarcy Library.